This site requires JavaScript to be enabled to work properly. Please modify your settings or use a different browser to continue

      

You are leaving GSKpro website

The information you are about to be referred to may not comply with the Australian regulatory requirements. Further information relevant to the Australian environment is available from the company or via the Product Information.

Continue

Go back

NP-AU-NA-WCNT-190017

Dosing for patients with asthma 1-2

  • Make patients aware that Breo Ellipta must be used regularly, even when asymptomatic.
  • Breo Ellipta should be administered at the same time every day.
  • Guidelines advise that all patients with asthma to carry a reliever containing a rapid onset β2 agonist at all times.
  • ICS should be used at the lowest dose that maintains symptom control.
  • After inhalation, the patient should rinse their mouth with water without swallowing.

References:

  1. Breo Ellipta Product Information
  2. National Asthma Council Australia. Australian Asthma Handbook, Version 2.1. National Asthma Council Australia, Melbourne, 2020. Website. Available from: http://www.asthmahandbook.org.au. Accessed October 2020

PBS Information – Authority Required (STREAMLINED): Asthma and Chronic Obstructive Pulmonary Disease. Criteria apply. Refer to PBS Schedule for full authority information.